Saudi FDA tells drug companies how to set up formal meetings
This article was originally published in SRA
The Saudi Food and Drug Authority has issued guidance on the procedure that drug companies should follow to set up formal meetings with the agency when they are looking for advice on a specific matter1. Among other things, the guideline explains that a meeting request should include an explanation of how the proposed meeting would be of use to the company because not all meeting requests are accepted by the SFDA.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.